About Evotec

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,900 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence.  The Evotec Group comprises the affiliate companies Aptuit, Cyprotex and Just – Evotec Biologics. Aptuit offers a complete set of integrated drug development solutions "under one roof" and specialises in integrated CMC as well as pre-clinical and IND-enabling GLP/GMP programs. Cyprotex specialises in in silico and in vitro ADME-Tox . Just – Evotec Biologics focuses on technologies to accelerate the development of biotherapeutics and substantially reduce their manufacturing cost. Core strengths are molecular design, process and product design as well as manufacturing plant design.

  • DE
  • 2019
    On CPhI since
  • 3
  • 1000 - 4999
Contract Service
Contact info

Evotec Resources